Skip to main content
main-content

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Our Editorial Board

Editor's pick

14-09-2018 | Screening | News

Meta-analysis consolidates evidence against PSA-based screening

Prostate-specific antigen-based screening may lead to a modest reduction in prostate cancer-specific mortality but has no effect on overall survival, say the authors of a meta-analysis published in The BMJ.

16-08-2018 | Non-small cell lung cancer | Article

Management of EGFR mutation-positive non-small-cell lung cancer: Two steps forward, looking back

Caroline McCoach (Helen Diller Family Comprehensive Cancer Center, CA, USA) and Howard (Jack) West (Swedish Cancer Institute, WA, USA) discuss the way forward after great progress with tyrosine kinase inhibitors targeting the epidermal growth factor receptor in non-small-cell lung cancer.

26-07-2018 | Non-small cell lung cancer | Editorial | Article

Choosing an immunotherapy approach in patients with advanced non-small-cell lung cancer

Liza Villaruz (Hillman Cancer Center, PA, USA) examines recent KEYNOTE trials investigating pembrolizumab for advanced non-small-cell lung cancer and the questions they raise regarding patient selection and combination therapy.

Specialty

Latest from across the site

19-09-2018 | Myelodysplastic syndrome | News

Persistent mutations post-transplant predict MDS disease progression

Persistent disease-associated mutations detected in the bone marrow 30 days after stem cell transplantation are associated with an increased risk for disease progression among patients with myelodysplastic syndrome, research shows.

Source:

N Engl J Med 2018; 379: 1028–1041

18-09-2018 | Supportive care | News

Allogeneic HSCT-treated patients often receive medically intense end-of-life care

A US research team has found that end-of-life care among individuals who undergo allogeneic hematopoietic stem cell transplantation can often be medically intense.

Source:

J Clin Oncol 2018; doi:10.1200/JCO.2018.78.095

18-09-2018 | EMA | News

approvalsWatch

Durvalumab, abemaciclib approvals announced by EMA

Click through to read more

17-09-2018 | Non-small cell lung cancer | News

FLAURA findings add to evidence for CNS efficacy of osimertinib in advanced NSCLC

Osimertinib treatment is associated with a reduced risk for central nervous system progression relative to erlotinib or gefitinib in patients with epidermal growth factor receptor-mutated, advanced non-small-cell lung cancer and brain metastases, trial results suggest.

Source:

J Clin Oncol 2018; doi:10.1200/JCO.2018.78.3118

14-09-2018 | EMA | News

approvalsWatch

EMA supports encorafenib plus binimetinib combination

Read more here

14-09-2018 | Screening | News

Meta-analysis consolidates evidence against PSA-based screening

Prostate-specific antigen-based screening may lead to a modest reduction in prostate cancer-specific mortality but has no effect on overall survival, say the authors of a meta-analysis published in The BMJ.

Source:

BMJ 2018; 362: k3519, k3702

Scientific summary

Diffuse large B-cell lymphoma management: Exploring novel treatment strategies

Diffuse large B-cell lymphoma management: Exploring novel treatment strategies

This program was made possible thanks to independent educational sponsorship from MorphoSys.

Gastric cancer care: From evidence to practice

Gastric cancer care

This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.

Soft tissue sarcoma: What is best practice?

 Soft tissue sarcoma: What is best practice?

This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.

Latest from us on Twitter

Updates from oncology organizations

New Content Item Meet our Advisory Board

image credits